GSK says split plans on track, forecasts dip in profit this year By Reuters

© Reuters. FILE PHOTO: Company logo of pharmaceutical company GlaxoSmithKline is seen at their Stevenage facility
© Reuters. FILE PHOTO: Company logo of pharmaceutical company GlaxoSmithKline is seen at their Stevenage facility

(Reuters) – Britain’s GSK said on Wednesday its plan to split into two businesses was on track, as the drugmaker aiding in COVID-19 vaccine developments forecast 2021 profit to fall by a mid- to high-single digit percentage.

The company, which earlier in the day announced a tie-up with CureVac to develop a COVID-19 vaccine, reported a 2% fall in turnover in the three months ended Dec. 31. Adjusted earnings came in at 23.3 pence per share.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.